| 1.245 0.005 (0.4%) | 10-15 12:17 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.99 | 1-year : | 2.35 |
| Resists | First : | 1.71 | Second : | 2.01 |
| Pivot price | 1.4 |
|||
| Supports | First : | 1.21 | Second : | 1 |
| MAs | MA(5) : | 1.3 |
MA(20) : | 1.41 |
| MA(100) : | 0.91  |
MA(250) : | 0.78 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7.1 |
D(3) : | 11.2 |
| RSI | RSI(14): 38.4 |
|||
| 52-week | High : | 2.34 | Low : | 0.27 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ EQ ] has closed above bottom band by 4.6%. Bollinger Bands are 20.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.3 - 1.31 | 1.31 - 1.32 |
| Low: | 1.18 - 1.2 | 1.2 - 1.21 |
| Close: | 1.22 - 1.25 | 1.25 - 1.26 |
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Mon, 06 Oct 2025
Connelly Promoted to President — Equillium Sharpening Focus on EQ504, Ends Biocon Itolizumab Collaboration - Stock Titan
Wed, 24 Sep 2025
Equillium (NASDAQ:EQ) Shares Down 2.8% - Here's What Happened - MarketBeat
Thu, 28 Aug 2025
Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC (NASDAQ:EQ) - Seeking Alpha
Tue, 12 Aug 2025
Financing at Equillium to advance EQ-504 into clinic - BioWorld MedTech
Mon, 11 Aug 2025
Equillium secures up to $50 million in private placement financing - Investing.com
Mon, 11 Aug 2025
Equillium Inc. Ventures into Cryptocurrency Strategy - timothysykes.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 60 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 20.9 (%) |
| Held by Institutions | 11.4 (%) |
| Shares Short | 2,180 (K) |
| Shares Short P.Month | 2,050 (K) |
| EPS | -0.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.14 |
| Profit Margin | -122 % |
| Operating Margin | -123.7 % |
| Return on Assets (ttm) | -46.4 % |
| Return on Equity (ttm) | -147 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.27 |
| Sales Per Share | 0.27 |
| EBITDA (p.s.) | -0.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -2.18 |
| PEG Ratio | 0 |
| Price to Book value | 8.85 |
| Price to Sales | 4.45 |
| Price to Cash Flow | -3.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|